These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Selective radionuclide localisation in primary liver tumours (pilot study). Novell JR; Green AJ; Hilson AJ; Dusheiko G; Dick R; Hobbs KE HPB Surg; 1994; 7(3):185-99; discussion 200. PubMed ID: 8155585 [TBL] [Abstract][Full Text] [Related]
4. Therapy of hepatocellular carcinoma with iodine-131-lipiodol. Results in a large German cohort. Risse JH; Rabe C; Pauleit D; Reichmann K; Menzel C; Grünwald F; Strunk H; Biersack HJ; Palmedo H Nuklearmedizin; 2006; 45(4):185-92. PubMed ID: 16964345 [TBL] [Abstract][Full Text] [Related]
5. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study. Brans B; De Winter F; Defreyne L; Troisi R; Vanlangenhove P; Van Vlierberghe H; Lambert B; Praet M; de Hemptinne B; Dierckx RA Cancer Biother Radiopharm; 2001 Aug; 16(4):333-8. PubMed ID: 11603004 [TBL] [Abstract][Full Text] [Related]
6. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma. De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257 [TBL] [Abstract][Full Text] [Related]
7. Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary? Bacher K; Brans B; Monsieurs M; De Winter F; Dierckx RA; Thierens H Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1311-6. PubMed ID: 12271412 [TBL] [Abstract][Full Text] [Related]
8. Ablation of recurrent primary liver cancer using 131I-lipiodol. Novell R; Hilson A; Hobbs K Postgrad Med J; 1991 Apr; 67(786):393-5. PubMed ID: 1648718 [TBL] [Abstract][Full Text] [Related]
9. Dosimetric assessment of radiolabelled lipiodol as a potential therapeutic agent in colorectal liver metastases using combined CT and SPECT. Perring S; Hind R; Fleming J; Birch S; Batty V; Taylor I Nucl Med Commun; 1994 Jan; 15(1):34-8. PubMed ID: 8152691 [TBL] [Abstract][Full Text] [Related]
10. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with Delaunay K; Edeline J; Rolland Y; Lepareur N; Laffont S; Palard X; Bouvry C; Le Sourd S; Pracht M; Ardisson V; Noiret N; Bellissant É; Garin E Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1506-1517. PubMed ID: 30715571 [TBL] [Abstract][Full Text] [Related]
11. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. Leung WT; Lau WY; Ho S; Chan M; Leung N; Lin J; Ho KC; Metreweli C; Johnson PJ; Li AK J Nucl Med; 1994 Aug; 35(8):1313-8. PubMed ID: 7519259 [TBL] [Abstract][Full Text] [Related]
12. 131I thyroid uptake in patients treated with 131I-Lipiodol for hepatocellular carcinoma. Toubeau M; Touzery C; Berriolo-Riedinger A; Cochet A; Brunotte F; Bedenne L; Cercueil JP; Krause D Eur J Nucl Med; 2001 May; 28(5):669-70. PubMed ID: 11383874 [No Abstract] [Full Text] [Related]
13. 18F-FDG-PET and histopathology in 131I-lipiodol treatment for primary liver cancer. Risse JH; Pauleit D; Bender H; Rabe C; Fischer HP; Biersack HJ; Bucerius J Cancer Biother Radiopharm; 2009 Aug; 24(4):445-52. PubMed ID: 19694579 [TBL] [Abstract][Full Text] [Related]
14. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. Lambert B; Bacher K; Defreyne L; Van Vlierberghe H; Jeong JM; Wang RF; van Meerbeeck J; Smeets P; Troisi R; Thierens H; De Vos F; Van de Wiele C Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):344-52. PubMed ID: 16333675 [TBL] [Abstract][Full Text] [Related]